This project is Memorial Sloan-Kettering Cancer Center's (MSKCC) application to become a Network Lead Academic Participating Site for the NCI National Clinical Trials Network (NCTN). The MSKCC project aims are scientific leadership in development of NCTN trials, scientific leadership in the activities of the NCTN and NCI Scientific Steering Committees, patient accrual on NCTN Trials, and mentoring junior investigators in clinical trial research. MSKCC has the resources to both bring strong scientifically driven studies to the network and to participate in studies brought forth by other network participants. MSKCC has a multidisciplinary team of investigators committed to translational research, a large patient population amenable to participation in clinical trials, an superb infrastructure to support such trials. MSKCC has full membership in Alliance for Clinical Trials in Oncology, GOG and RTOG and is an affiliate member of ECOG. MSKCC has strong leadership and expertise in advanced imaging and participates in ACRIN studies on a case-by-case basis. The multiple Principal Investigators in this Network Lead Academic Site U10 are experienced leaders in the Network Groups with a track record of meeting these scientific, accrual and mentoring aims. As a large center focused solely on cancer, we have a particular expertise and commitment to the NCTN mission of evaluating rare tumors.
As a Network Lead Academic Participating Site MSKCC will be a leader in the scientific development, conduct and accrual of NCTN clinical trials with the overall goal of developing new treatments for cancer patients. This will be achieved through definitive, randomized, clinical treatment and advanced imaging trials across a broad range of diseases and diverse patient populations, as well as development efforts preliminary to those trials.
|Tanioka, Maki; Fan, Cheng; Parker, Joel S et al. (2018) Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. Clin Cancer Res 24:5292-5304|
|Fadelu, Temidayo; Zhang, Sui; Niedzwiecki, Donna et al. (2018) Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance). J Clin Oncol 36:1112-1120|
|Straus, David J; Jung, Sin-Ho; Pitcher, Brandelyn et al. (2018) CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood 132:1013-1021|
|Ignatz-Hoover, James J; Wang, Victoria; Mackowski, Nathan M et al. (2018) Aberrant GSK3? nuclear localization promotes AML growth and drug resistance. Blood Adv 2:2890-2903|
|Miller, Kathy D; O'Neill, Anne; Gradishar, William et al. (2018) Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103). J Clin Oncol 36:2621-2629|
|Guercio, Brendan J; Zhang, Sui; Niedzwiecki, Donna et al. (2018) Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance). PLoS One 13:e0199244|
|Van Blarigan, Erin L; Fuchs, Charles S; Niedzwiecki, Donna et al. (2018) Marine ?-3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance). Cancer Epidemiol Biomarkers Prev 27:438-445|
|Choueiri, Toni K; Hessel, Colin; Halabi, Susan et al. (2018) Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eu Eur J Cancer 103:287|
|Byrd, John C; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Adv 2:1705-1718|
|Choueiri, Toni K; Hessel, Colin; Halabi, Susan et al. (2018) Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. Eur J Cancer 94:115-125|
Showing the most recent 10 out of 77 publications